Twist Bioscience Expands North American Presence with Office in San Diego, California Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA, today announced it has expanded its North American operations with a new … Continued
Inscripta Raises $55.5 Million to Advance Gene-Editing Technology Investment will grow company’s expert team, accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and software Inscripta, a leading gene-editing technology company, today announced that it has closed … Continued
Cedars-Sinai and Emulate, Inc. Announce Patient-on-a-Chip Program Using Stem Cells and Organs-on-Chips Technology for Precision Medicine Scientists at Cedars-Sinai and Emulate, Inc.are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient’s genetic makeup and … Continued
Emulate and Takeda Partner to Use Intestine-Chip for New Drug Target Identification and Validation in Drug Development for GI Diseases Emulate announced today that it has formed a strategic R&D collaboration with Takeda Pharmaceutical Company Limited to use Emulate’s Intestine-Chip … Continued
Emulate partners with Roche for drug discovery Emulate announced today that it has formed a strategic partnership with F Hoffman La-Roche AG (Roche) that will use Emulate’s Human Emulation System across R&D programs to enable more human-relevant studies that will … Continued
ARMO BioSciences Announces Pricing of Initial Public Offering ARMO BioSciences, Inc. (“ARMO”), a late-stage immuno-oncology company, today announced the pricing of its initial public offering of 7,529,412 shares of its common stock at a price to the public of $17.00 per share for … Continued